Depression is a severe and recurrent neuropsychiatric disease with high prevalence, disability, and mortality, which imposes a heavy burden on national public health and the economy. Traditional antidepressants demonstrate delayed effects, low cure rates, and inadequate therapeutic effectiveness for managing treatment-resistant depression. Numerous studies have proved that esketamine, a...
Ketamine is currently gaining attention as a rapid-acting antidepressant for treatment-resistant depression (TRD). However, many patients fail to respond, and limited data exist on predictors of non-response. This study aims to characterize the sociodemographic and clinical features associated with non-response to ketamine among TRD patients. This is a post-hoc analysis of a naturalistic...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by significant morbidity and mortality. The emergence of ketamine infusion therapy has provided a promising, rapidly acting treatment option. We aimed to assess the effectiveness of ketamine infusion therapy as an adjunct treatment in patients with depression and to study the patient's profile undergoing...
Introduction: High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing...
Introduction: Treatment-resistant depression (TRD) affects over 30 % of patients with depression and is associated with high morbidity and mortality. Intravenous (IV) ketamine has shown rapid and robust antidepressant effects for TRD. However, limited data exist on long-term maintenance and patient experiences, especially in North America. This study aims to explore the lived experiences of...
Abstract Psilocybin therapy (PT) is emerging as an effective intervention for Major Depressive Disorder (MDD), offering comparable efficacy to conventional treatments like selective serotonin reuptake inhibitors (SSRIs). Music, an emotionally evocative stimulus, provides a valuable tool to explore changes in hedonic and predictive processing mechanisms via expectancy violations, or ‘surprises’....
Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. One...
Background: Esketamine is a rapidly acting antidepressant with robust efficacy in treatment-resistant depression (TRD). Diminishing therapeutic effects and attenuated side effects have been reported after long-term use. This study aimed to investigate its long-term pharmacokinetics and factors that may contribute to reduced efficacy over time in patients with TRD by evaluating the potential...
Objective To evaluate psilocybin's efficacy in reducing depressive and anxiety symptoms in cancer patients based on randomized controlled trials (RCTs). Methods This systematic review and network meta-analysis (NMA) followed PRISMA and Cochrane Handbook guidelines. PubMed, Embase and Cochrane Library data up to July 2024 were analyzed. Two RCTs met the inclusion criteria. Changes in Beck...
The evidence that mindfulness-based programmes (MBPs) improve the mental health and well-being of social workers is growing. Which MBP mechanisms improve these outcomes is unclear. This study attempts to identify what these mechanisms might be, using data from two RCTs investigating the impact of the MBP participation on social worker depression, anxiety, and mental well-being. Structural...